Understanding an Elevated Result

A guide to understanding risk and taking action

REPORT EXAMPLE

Integrated BRACAnalysis with Myriad myRisk® Hereditary Cancer

myRisk Genetic ResultRECEIVING HEALTHCARE PROVIDERTest HCP, MDTest Medical Center123 Main StTestville, TX 55555

SPECIMENSpecimen Type: BloodDraw Date: Jan 30, 2018Accession Date: Jan 30, 2018Report Date: Feb 02, 2018

PATIENTName: Pt Last Name,

Pt First NameDate of Birth: Jan 30, 1979Patient ID: Patient idGender: FemaleAccession #: Requisition #:

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIEDNote: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated withthe potential to alter medical intervention.

BREAST CANCER RISKSCORETM: REMAINING LIFETIME RISK 31.1%This level of risk is at or above 20% threshold for consideration of modified medical management.See riskScoreTM Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: BASED ON THE CLINICAL HISTORY PROVIDED,MODIFIED MANAGEMENT GUIDELINES IDENTIFIEDOther clinical factors may influence individualized management. This analysis may be incomplete if detailsabout cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase anindividual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (FavorPolymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not causeincreased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medicalmanagement beyond what is indicated by the personal and family history and any other clinically significant findings.

Variant Classification: Myriad's myVisionTM Variant Classification Program performs ongoing evaluations of variant classifications. In certaincases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When newevidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically bemade available to the healthcare provider through an amended report.

ADDITIONAL INFORMATIONIndication for Testing: It is our understanding that this individual was identified fortesting due to a personal or family history suggestive of a hereditary predisposition forcancer.

Associated Cancer Risks and Clinical Management: Please see the "myRiskManagement Tool" associated with this report for a summary of cancer risk andprofessional society medical management guidelines that may be useful in developing aplan for this patient based on test results and reported personal/family history, ifapplicable. Testing of other family members may assist in the interpretation of thispatient's test result.

Analysis Description: The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the analysis, method,performance, nomenclature, and interpretive criteria of this test. Current testingtechnologies are unable to definitively determine whether a variant is germline or somaticin origin, which may significantly impact risk estimates and medical management;therefore, these results should be correlated with this patient's personal and familyhistory. The interpretation of this test may also be impacted if the patient has ahematologic malignancy or an allogeneic bone marrow transplant.

GENES ANALYZED

Unless otherwise noted sequencing and largerearrangement analyses were performed on thefollowing genes:

APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2,BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM(large rearrangement only), MLH1, MSH2, MSH6,MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C,RAD51D, SMAD4, STK11, TP53. Sequencing wasperformed for select regions of POLE and POLD1,and large rearrangement analysis was performed forselect regions of GREM1 (see technicalspecifications).

** Other genes not analyzed with this test may also beassociated with cancer.

myRisk Genetic Result: Page 1 of 3

© 2018 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad myRisk,riskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of MyriadGenetics, Inc. in the United States and other jurisdictions.

A. Your Myriad myRisk® Hereditary Cancer result

summary is located on the first page of your report.

It will look similar to the example shown to the right.

If you received an ELEVATED myRisk Hereditary

Cancer result it means:

1. Your myRisk Genetic Result is NEGATIVE. You

tested negative for any clinically significant

changes (called mutations) in the genes analyzed

on the myRisk Hereditary Cancer panel. Based on

this, your risk for a hereditary cancer syndrome is

lower but not completely ruled out.

Although your genetic result was negative you

are still at an ELEVATED risk of cancer based

on either your breast cancer riskScore® or your

Clinical History Analysis. One or both of these

analyses identified modified medical management

as indicated by an orange asterisk . A summary

of medical management recommendations based

on leading medical society guidelines will be

provided in the myRisk Management Tool section

of your report.

2. Your result may contain a breast cancer

riskScore®. If the riskScore was performed, details

will be provided on the following page of your

Genetic Test Result (see D.)

3. Your result will contain a Clinical History Analysis.

This analysis was based on personal clinical risk

factors and the cancer family history you reported

to your provider.

B. In addition to your elevated result, your testing

may have found one or more “Variants of Uncertain Significance (VUS).” A VUS is not currently known to

be associated with an increased cancer risk. Myriad

has made a lifetime commitment to understanding

the nature of these variants. If new evidence about

a variant is identified, that information will be made

available to your healthcare provider who will then

contact you with updated information. It is important

to understand that medical management decisions

should not be based on the VUS result.

C. You can find a list of all the genes tested in the

Genes Analyzed section.

A

B

C

Your test result may include three parts: your Genetic Test Result, your breast cancer riskScore®

(if applicable), and your Clinical History Analysis.

PART ONE:

1 Understanding an Elevated Result

Genetic Test Result

REPORT EXAMPLE

myRisk Genetic ResultName: DOB:Pt Last Name, Pt First Name Jan 30, 1979 Accession #: Report Date: Feb 02, 2018

Breast Cancer riskScore®

Breast CancerriskScoreTM:

31.1%RESULT: 31.1% Remaining Lifetime Risk for Breast Cancer

1.5% 5-Year Risk for Breast Cancer

GeneralPopulation

ThisPatient

Breast Cancer riskScoreTM - Remaining Lifetime Risk20% RiskThreshold

Average Risk Above Average Risk

>

BREAST CANCER RISKSCORETM INTERPRETATION

The breast cancer riskScoreTM provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate at or above 20% is associated withspecific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reductionmeasures. If applicable, details of these recommendations are provided in the accompanying myRisk Medical Management Tool or othersupplemental material. Women with a risk estimate below 20% may still be appropriate for consideration of modified medical management based onother clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick, Claus, and Gail.

BREAST CANCER RISKSCORETM ANALYSIS DESCRIPTION

The breast cancer riskScoreTM provides 5-year and remaining lifetime breast cancer risks, based on an analysis of genetic markers combined withpatient clinical and family history data. The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the riskScoreTM eligibility criteria, analysis, method, performance and interpretive criteria of this test. Data from 86biomarkers are analyzed during next generation sequencing (NGS). The allele status of these markers is weighted and combined with patient clinicaland family history data in the riskScoreTM calculation. The Clinical and Cancer Family History Information section of this report displays the data usedfor this analysis and explains important limitations on the accuracy of riskScore (including significant over- or under-estimates of breast cancer risk)that can be caused by errors and/or omissions in the reported clinical and family history data.

TYRER-CUZICK BREAST CANCER RISK CALCULATION

REMAINING LIFETIME BREAST CANCER RISK: 18.5% 5-YEAR BREAST CANCER RISK: 0.8%

The National Comprehensive Cancer Network (NCCN) provides medical management recommendations for women with an estimated remaininglifetime breast cancer risk greater than 20% based on Tyrer-Cuzick. These recommendations are summarized on the myRisk Management Tool(MMT). If an MMT is not included with this report, current management recommendations from the NCCN Breast Cancer Screening and Diagnosispanel can be accessed at www.nccn.org. Version 7.02 of the Tyrer-Cuzick model was used for this risk estimate. Tyrer-Cuzick model Versions 7.02and 8.0 are available for download at the EMS-Trials website, http://www.ems-trials.org/riskevaluator.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

This Authorized Signaturepertains to this laboratory report:

Benjamin B. Roa, PhDDiplomate ABMGLaboratory Director

Johnathan M. Lancaster, MD, PhDDiplomate ABOG, FACOG, FACSChief Medical Officer

These test results should only be used in conjunction with the patient's clinicalhistory and any previous analysis of appropriate family members. The patient'sclinical history and test results should not be disclosed to a third party, unlessrelated to treatment or payment for treatment, without the patient's express writtenauthorization. It is strongly recommended that these results be communicated tothe patient in a setting that includes appropriate genetic consultation. This test wasdeveloped and its performance characteristics determined by Myriad GeneticLaboratories. It has not been cleared or approved by the U.S. Food and DrugAdministration (FDA). The FDA has determined that clearance or approval forlaboratory-developed tests is not required.

myRisk Genetic Result: Page 3 of 3

© 2018 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad myRisk,riskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of MyriadGenetics, Inc. in the United States and other jurisdictions.

REPORT EXAMPLE

Integrated BRACAnalysis with Myriad myRisk® Hereditary CancerClinical & Cancer Family History Information

RECEIVING HEALTHCARE PROVIDERTest HCP, MDTest Medical Center123 Main StTestville, TX 55555

SPECIMENSpecimen Type: BloodDraw Date: Jan 30, 2018Accession Date: Jan 30, 2018Report Date: Feb 02, 2018

PATIENTName: Pt Last Name,

Pt First NameDate of Birth: Jan 30, 1979Patient ID: Patient idGender: FemaleAccession #: Requisition #:

PATIENT CLINICAL HISTORY SUMMARY

Woman's age 39

Ancestry White/Non-Hispanic

Height 5 ft 7 in

Weight 175 lbs

Age of menarche 13

Patient's menopausal status Pre-menopausal

- Age of onset N/A

Age of first live birth 27

Hormone Replacement Therapy (HRT) No

- HRT: Treatment type N/A

- HRT: Current user N/A

- Number of years ago started N/A

- Additional years of intended use N/A

- HRT: Past user N/A

- Number of years ago ended N/A

Breast biopsy Not Specified

PERSONAL / FAMILY CANCER HISTORY SUMMARY

FAMILY MEMBER CANCER / CLINICAL DIAGNOSIS AGE AT DIAGNOSIS

Patient Colorectal Polyps: 1 Not Provided

Aunt Paternal Breast, Invasive 62

Father Colorectal Polyps: 100-999 52

Uncle Paternal Melanoma 45±

Brother Colorectal Polyps: # Not Specified 36

NUMBER OF PATIENT'S FEMALE RELATIVES

Daughters 1 Sisters 2 Maternal Aunts 2 Paternal Aunts 2

The clinical information displayed here was provided by a qualified healthcare provider on the Test Request Form and other documents, and was not verified byMyriad. Family members listed as "other" are not included in a Tyrer-Cuzick breast cancer risk estimate or other personal/family history assessments. For moreinformation see the Specifications for Personal/Family History Analysis at https://www.myriadpro.com/documents-and-forms/technical-specifications/. The accuracy ofthe information provided in the Clinical and Cancer Family History Information section of the report may significantly affect the accuracy of breast cancer riskestimates provided based on either Tyrer-Cuzick or riskScoreTM.

riskScoreTM is only calculated for women who meet the eligibility criteria listed below. riskScoreTM is not valid, and may significantly over- or under-estimate breastcancer risk for a woman who does not meet these criteria: 1) ancestry is exclusively White/Non-Hispanic (includes Ashkenazi Jewish), 2) age is 85 or younger, 3) nopersonal history of breast cancer, LCIS, hyperplasia (with or without atypia), or a breast biopsy with unknown results, 4) no known mutation in a breast cancer riskgene has been found in the woman or any of her relatives, and 5) the sample was submitted with a current Test Request Form and the ordering healthcare providerhas not determined that riskScoreTM is inappropriate for the patient.

± Age estimate based on information given. A more specific age may change cancer risk management suggestions provided.

Clinical Information: Page 1 of 1

© 2018 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad myRisk,riskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of MyriadGenetics, Inc. in the United States and other jurisdictions.

D. If the riskScore® was performed, this page of

your Genetic Test Result will contain details of

the analysis. This page displays an estimate of

your remaining lifetime risk for breast cancer as

well as your risk over the next five years. You can

compare your risk to the general population using

the graph provided.

If the analysis identified any modified medical

management based on your riskScore, an

orange asterisk will appear next to your

score. A summary of medical management

recommendations based on leading medical

society guidelines will be provided in the myRisk

Management Tool section of your report.

E. The Clinical and Cancer Family History Information Page displays the information

regarding your clinical history and personal and

cancer family history you reported.

D

If you have additional questions about your result please contact your healthcare provider. Myriad’s Medical Services team is also available to help:

(800) 469-7423 x3850 / helpmed@myriad.com

E

REPORT EXAMPLE

Integrated BRACAnalysis with Myriad myRisk® Hereditary Cancer

myRisk Management ToolRECEIVING HEALTHCARE PROVIDERTest HCP, MDTest Medical Center123 Main StTestville, TX 55555

SPECIMENSpecimen Type: BloodDraw Date: Jan 30, 2018Accession Date: Jan 30, 2018Report Date: Feb 02, 2018

Name: Pt Last Name,Pt First Name

Date of Birth: Jan 30, 1979Patient ID: Patient idGender: FemaleAccession #: Requisition #:

PATIENT

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIEDNote: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated withthe potential to alter medical intervention.

BREAST CANCER RISKSCORETM: REMAINING LIFETIME RISK 31.1%This level of risk is at or above 20% threshold for consideration of modified medical management.See riskScoreTM Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: BASED ON THE CLINICAL HISTORY PROVIDED,MODIFIED MANAGEMENT GUIDELINES IDENTIFIEDOther clinical factors may influence individualized management. This analysis may be incomplete if detailsabout cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous.

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may still beincreased over the general population. See information below.

BREAST CANCER RISKSCORETM THIS BREAST CANCER RISKSCORETM IS ASSOCIATED WITHTHE FOLLOWING CANCER RISKS:

At or above 20% ELEVATED RISK: Female Breast

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

TYRER-CUZICK BREAST CANCER RISK CALCULATION

REMAINING LIFETIME BREAST CANCER RISK: 18.5% 5-YEAR BREAST CANCER RISK: 0.8%

The Tyrer-Cuzick breast cancer risk estimate is not calculated if one or more of the following conditions apply: the woman is known to carry amutation in a gene associated with breast cancer risk, age is 85 or older, if the sample was submitted with a version of the Test Request Form thatdoes not include all of the fields required to collect the clinical information used in the calculation, or if the provider indicates on the Test RequestForm that the Tyrer-Cuzick calculation is not appropriate for the patient. Version 7.02 of the Tyrer-Cuzick model was used for this risk estimate.Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials website, http://www.ems-trials.org/riskevaluator.

myRisk Management Tool: Page 1 of 4

© 2018 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad myRisk,riskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of MyriadGenetics, Inc. in the United States and other jurisdictions.

Your future risk of cancer is influenced by your Genetic Test Result, your personal clinical

history and your family history of cancer. The myRisk Management Tool provides a summary

of your future risks based on your genetic result and the information provided to Myriad, but

additional risk factors may be present and should be discussed with your provider.

F. If you received an Elevated result, despite

testing negative for any gene mutations you are

still at ELEVATED risk for one or more cancers

based on personal clinical factors, your family

history of cancer, and/or your riskScore®.

G. If you are a woman, your elevated risk may

be a result of your riskScore®. riskScore is only

calculated for women under age 85, of solely

White / Non-Hispanic and/or Ashkenazi Jewish

ancestry, without a personal history of breast

cancer, LCIS, hyperplasia, atypical hyperplasia,

or a breast biopsy with unknown results.

riskScore® is not calculated if a woman or blood

relative is known to carry a mutation in a breast

cancer risk gene. This score is calculated using

both genetic and non-genetic factors that may

be shared within your family. If your riskScore

is calculated to be 20% or higher, modified

medical management recommendations will be

summarized later in the report.

H. Your elevated risk may be a result of the

analysis of your clinical history. If you are a

woman who has never been diagnosed with

breast cancer and have no relatives with a

known genetic mutation, you will also receive

a Tyrer-Cuzick Risk Calculation. Tyrer-Cuzick

is a model used to predict a woman’s risk of

developing breast cancer which was developed

by leading researchers. Tyrer-Cuzick takes

into consideration your family history of

cancer and other personal clinical risk factors.

If your Tyrer-Cuzick Risk Calculation is 20%

or higher, modified medical management

recommendations will be summarized later in

the report.

F

G

H

PART TWO:

2

myRisk Management Tool

3

Understanding an Elevated Result

REPORT EXAMPLE

myRisk Management ToolName: DOB:Pt Last Name, Pt First Name Jan 30, 1979 Accession #: Report Date: Feb 02, 2018

OVERVIEWRemaining Lifetime Breast Cancer Risk Estimated to be 20% or Higher:• This woman has an estimated remaining lifetime risk for breast cancer at or above the 20% threshold based on riskScoreTM. This is the

estimated risk of developing breast cancer from this woman's current age to age 85.• riskScoreTM is partially based on the analysis of selected genetic markers known to have an impact on breast cancer risk. Although the level of

risk associated with each individual marker is small, results from the combined analysis of multiple markers can have a significant impact onbreast cancer risk estimates.

• The riskScoreTM estimate is also based on information about the woman's personal medical history and any history of breast and ovarian cancerin her relatives. riskScoreTM will be less accurate if any of the information that was provided is incomplete or incorrect.

• Currently there are no guidelines for the medical management of breast cancer risk in women based on riskScoreTM. However, it may beappropriate to consider options based on guidelines for other situations where the estimated remaining lifetime breast cancer risk is at or abovethe 20% threshold.

WHAT ARE THE PATIENT'S GENE-RELATED CANCER RISKS?If more than one gene mutation increases a specific cancer risk (e.g., breast), only the highest cancer risk is shown. If this patient has more than onegene mutation, risks may be different, as this analysis does not account for possible interactions between gene mutations.

CANCER TYPE CANCER RISKRISK FOR

GENERAL POPULATION RELATED TO

Current age to age 85 31.1% 13.0% riskScoreTM at or above the20% threshold

FEMALE BREAST

WHAT MANAGEMENT FOR CANCER RISKS SHOULD BE CONSIDERED?This overview of clinical management guidelines is based on the patient's personal and family history and genetic test results. Medical managementguidelines are summarized from established medical societies, primarily the National Comprehensive Cancer Network (NCCN). The reference citedshould always be consulted for more details. If management for a specific cancer (e.g. breast) is available due to multiple causes (e.g. a mutation and aTyrer-Cuzick risk estimate >20%, or multiple mutations in different genes), only the most aggressive management is shown. Only guidelines for thepatient's long-term care related to cancer prevention are included.

No information is provided related to treatment of a previous or existing cancer or polyps. The recommendation summaries below may requiremodification due to the patient's personal medical history, past surgeries and other treatments. Patients with a past history of cancer, benign tumors, orpre-cancerous findings may be candidates for long term surveillance and risk-reduction strategies beyond what is necessary for the treatment of theirinitial diagnosis. Any discussion of medical management options is for general information purposes only and does not constitute a recommendation.While genetic testing and medical society recommendations provide important and useful information, medical management decisions should be madein consultation between each patient and his or her healthcare provider.

myRisk Management Tool: Page 2 of 4

© 2018 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad myRisk,riskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of MyriadGenetics, Inc. in the United States and other jurisdictions.

Medical Management

Information for Family MembersPART THREE:3If no mutations were found in the genes we tested, your relatives may not

need genetic testing.

However, in some cases, genetic testing should be offered to another

relative, especially if they have been diagnosed with a cancer associated

with the suspected hereditary cancer genes for which you were tested. This

can provide more information about hereditary risk for you and others in

your family. Talk to your healthcare provider to help determine whether any

further genetic testing should be offered to you or to a family member.

If your risk of breast cancer was estimated to be above average using

riskScore®, your female relatives may also be at an increased risk for breast

cancer. Your relatives may want to consult with a healthcare provider to

discuss their possible risk.

I

I. The myRisk Medical Management Tool provides a

summary of management recommendations from leading

medical societies that you and your healthcare provider

may consider. In general, changes to your cancer risk

management can take three possible directions:

1. You may be screened more often and perhaps with

different or additional tests than you have had

previously.

2. It might also be recommended that you take

medications (known as risk-reducing agents) to

reduce your risk.

3. You may discuss lifestyle changes with your provider.

Your healthcare provider will work with you to determine

the best medical management plan for you. Be sure to

contact your healthcare provider on a regular basis for

updated information.

Notes

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Hereditary Cancer Testing Provided by: Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108

Myriad, the Myriad logo, Myriad myRisk, the Myriad myRisk logo, riskScore the riskScore logo, mySupport360, and the mySupport360 logo are either trademarks

or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2018, Myriad Genetic Laboratories, Inc. MRHCELEVPET / 7-18

Next Steps

Schedule any follow-up appointments

Speak with your family members about your result and encourage them to see their healthcare provider about cancer prevention and testing

Consider speaking with a genetic counselor about your test result and family history

Working with your healthcare provider, the two of you will determine the appropriate next steps for you. Here are some possible actions to consider:

ResourcesPATIENT SUPPORT

Your healthcare provider is always your number one resource. You are also

invited to visit www.mySupport360.com, the Myriad program offering

information and support for patients. You will find valuable information that will

help you better understand your test result, and you can join a community of

people who are on the same hereditary cancer testing journey as you.

You may also contact Myriad’s Medical Services team at 1-800-469-7423 x3850

to speak to a genetic counselor.